Trial reportCancer immunology, immunotherapy : CII2012
Assessment of association between BRAF-V600E mutation status in melanomas and clinical response to ipilimumab.
Trial report in Cancer immunology, immunotherapy : CII, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 84 citations in OpenAlex.
- Nivolumab and ipilimumab versus ipilimumab in untreated melanoma.The New England journal of medicine · 2015Trial
- Metabolic Profiling to Assess Response to Targeted and Immune Therapy in Melanoma.International journal of molecular sciences · 2024Review
- Case report: Later onset of NRAS-mutant metastatic melanoma in a patient with a partially-excised giant congenital melanocytic nevus.Frontiers in medicine · 2022Article
- Uncommon Subtypes of Malignant Melanomas: A Review Based on Clinical and Molecular Perspectives.Cancers · 2020Review
- [Research Progress of Immune Checkpoint Inhibitor Therapy for BRAF Mutation in Non-small Cell Lung Cancer].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2019Review
- Role of tumor gene mutations in treatment response to immune checkpoint blockades.Precision clinical medicine · 2019Review
- Patterns of treatment and BRAF testing with immune checkpoint inhibitors and targeted therapy in patients with metastatic melanoma presumed to be BRAF positive.Melanoma research · 2019Article
- Weighted correlation network and differential expression analyses identify candidate genes associated with BRAF gene in melanoma.BMC medical genetics · 2019Article
- Emerging biomarkers for cancer immunotherapy in melanoma.Seminars in cancer biology · 2018Review
- Biomarkers for Clinical Benefit of Immune Checkpoint Inhibitor Treatment-A Review From the Melanoma Perspective and Beyond.Frontiers in immunology · 2018Review
- Biomarkers for Response of Melanoma Patients to Immune Checkpoint Inhibitors: A Systematic Review.Frontiers in oncology · 2017Article
- Review
- Clinical use of ipilimumab for metastatic melanoma in Spain: towards a more consistent approach.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2016Article
- Biology and treatment of BRAF mutant metastatic melanoma.Melanoma management · 2016Review
- Liquid Biopsies for Assessing Metastatic Melanoma Progression.Critical reviews in oncogenesis · 2016Review
- Impact of NRAS mutations for patients with advanced melanoma treated with immune therapies.Cancer immunology research · 2015Article
- Article
- Biomarkers in melanoma: where are we now?Melanoma management · 2014Review
- Novel anti-melanoma treatment: focus on immunotherapy.Chinese journal of cancer · 2014Article
- Emerging targeted therapies for melanoma treatment (review).International journal of oncology · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ipilimumab, a fully human monoclonal antibody against cytotoxic T lymphocyte antigen-4, has demonstrated significant improvement in overall survival in previously treated advanced melanoma patients. The BRAF inhibitor, vemurafenib, has shown up to 78% objective response rates in melanoma patients harboring the BRAF-V600E mutation but not in patients lacking the mutation. As an immune potentiator, the mechanism of action of ipilimumab may not be dependent of the activity of the BRAF pathway. To test this, we investigated whether the clinical activity of ipilimumab would be affected by the BRAF-V600E mutation status of the tumors. Thus, this retrospective analysis was carried using a set of tumor biopsies from a completed phase II clinical trial. CA184004 was a randomized, double-blind, multicenter trial of 82 previously treated or untreated patients with unresectable stage III/IV melanoma. Patients received ipilimumab 3 or 10 mg/kg every 3 weeks for four doses followed by maintenance dosing in eligible patients. The BRAF-V600E mutation status for 80 patients was determined in tumor biopsies by PCR-based assays. Data on disease control were available for 69 patients with evaluated BRAF-V600E mutation status. Rates of objective responses and stable disease in patients with BRAF-V600E mutation positive tumors (30%) were comparable to those in patients with the wild-type gene (~33%). Eleven patients displayed Durable Disease Control (DDC) of which 55% had BRAF-V600E mutation positive tumors and 45% did not. In the 48 patients showing no DDC, the mutation frequency was 50%. In this study, no association between BRAF-V600E mutation status of melanoma tumors and DDC after treatment with ipilimumab was detected.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.